194 related articles for article (PubMed ID: 37000008)
21. Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma.
Zhang Y; Liu Y; Xia Z; Jin J; Xue K; Wang J; Sun H; Lv F; Liu X; Cao J; Hong X; Guo Y; Ma X; Zhang Q
Ann Transl Med; 2021 Jul; 9(14):1178. PubMed ID: 34430619
[TBL] [Abstract][Full Text] [Related]
22. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
[TBL] [Abstract][Full Text] [Related]
23. [A multi-center retrospective study of L-asparaginase-based regimens as first-line treatment in newly diagnosed extranodal NK/T-cell lymphoma].
Yuan F; Wei X; Yin Q; Li Y; Mi R; Ai H; Yang H; Li H; Ge S; Liu Y; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):614-8. PubMed ID: 25052604
[TBL] [Abstract][Full Text] [Related]
24. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
Dong LH; Zhang LJ; Wang WJ; Lei W; Sun X; Du JW; Gao X; Li GP; Li YF
Leuk Lymphoma; 2016 Jul; 57(7):1600-6. PubMed ID: 26726970
[TBL] [Abstract][Full Text] [Related]
25. "Sandwich" protocol based on modified SMILE regimen for children with newly extranodal NK/T cell lymphoma, nasal type: a single-arm, single-center clinical study.
Shen CQ; He GQ; Wan Z; Lin C; Yang X; Lu XX; Zhu YP; Gao J; Guo X
Ann Hematol; 2023 Nov; 102(11):3143-3152. PubMed ID: 37486391
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
Li JW; Li YJ; Zhong MZ; Liu XL; Li J; Li KL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Zhou H; Yi PY
Eur J Haematol; 2018 Mar; 100(3):247-256. PubMed ID: 29194798
[TBL] [Abstract][Full Text] [Related]
27. The Clinical Features and Survival Outcome of 107 Newly Diagnosed Advanced Stage Extranodal NK/T-Cell Lymphoma Cases: A Triple-Center Study.
Li J; Li J; Zhong M; Zhou H; Yu B
Cancer Manag Res; 2021; 13():1541-1549. PubMed ID: 33623433
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.
Zhang L; Jia S; Ma Y; Li L; Li X; Wang X; Fu X; Ma W; Qin Y; Li W; Wu J; Sun Z; Zhang X; Nan F; Chang Y; Li Z; Zhang D; Wang G; Yan J; Su L; Wang J; Xue H; Young KH; Zhang M
Oncotarget; 2016 Aug; 7(34):55721-55731. PubMed ID: 27384676
[TBL] [Abstract][Full Text] [Related]
29. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Zhang L; Li S; Jia S; Nan F; Li Z; Cao J; Fan S; Zhang C; Su L; Wang J; Xue H; Zhang M
Oncotarget; 2016 Sep; 7(36):58396-58404. PubMed ID: 27517317
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.
Liu Y; Xue K; Xia Z; Jin J; Wang J; Sun H; Lv F; Liu X; Cao J; Hong X; Guo Y; Ma X; Zhang Q
Cancer Med; 2020 Aug; 9(15):5400-5405. PubMed ID: 32519518
[TBL] [Abstract][Full Text] [Related]
31. Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Wei C; Cao X; Zhang W; Zhang Y; Wang W; Zhang L; Yang C; Feng J; Cai H; Chen M; Mao Y; Zhou D
Ann Hematol; 2020 Dec; 99(12):2801-2809. PubMed ID: 32399707
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of prognostic factors of extranodal NK/T-cell lymphoma treated with pegaspargase/L-asparaginase: a multicenter retrospective study].
Shen ZY; Chen XC; Shan HR; Jia T; Gu WY; Wang F; Teng QL; Wang L; Wang CL; Shi YY; Zhang H; Miao YQ; Zhu TG; Ji CY; Ye JJ; Zhang MZ; Zhang XD; Wang L; Xu KL; Sang W
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):642-648. PubMed ID: 37803837
[No Abstract] [Full Text] [Related]
33. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
Wei L; Wang J; Ye J; Yang L; Cong J; Li X; Wu Y; Cui X; Ding J; Yao N; Yang J
Leuk Lymphoma; 2020 Feb; 61(2):337-343. PubMed ID: 31517553
[TBL] [Abstract][Full Text] [Related]
36. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Wang L; Wang ZH; Chen XQ; Li YJ; Wang KF; Xia YF; Xia ZJ
Cancer; 2013 Jan; 119(2):348-55. PubMed ID: 22811078
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Chaubard S; Marouf A; Lavergne D; Lemonnier F; Rossignol J; Clavert A; Gressin R; Cartron G; Waultier-Rascalou A; Vargaftig J; Salles G; Bachy E; Ghesquières H; Tournilhac O; Chauchet A; Le Gouill S; Damaj G; Fornecker LM; Sibon D; Obéric L; Michot JM; Gaulard P; Hermine O; Couronné L; Jaccard A
Br J Haematol; 2023 May; 201(4):673-681. PubMed ID: 36799516
[TBL] [Abstract][Full Text] [Related]
38. Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
Huang Y; Yang J; Liu P; Zhou S; Gui L; He X; Qin Y; Zhang C; Yang S; Xing P; Sun Y; Shi Y
Ann Hematol; 2017 Sep; 96(9):1477-1483. PubMed ID: 28695246
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of GLIDE chemotherapy for patients with newly diagnosed advanced-stage or relapsed/refractory extranodal natural killer cell lymphoma].
Ji J; Xiang B; Liu ZG; Jia YQ; Zhu HL; Niu T; Pan L; Chang H; Huang J; Wu Y; Li JJ; He C; Ma HB; Tang Y; Dong T; Liu T
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):751-755. PubMed ID: 27719716
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]